3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction

Fiori, Cristian; Valério, Massimo; Schulman, Claude; Giannakis, I.; Cillis, Sabrina De; Kadner, Gregor; Porpiglia, Francesco

doi:10.1038/s41391-020-00281-5

Cited by 43 publications

(22 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three prospective, randomized clinical trials (n=269) have demonstrated IPSS reduction of -45% to -60%, Qmax increase in +50% to +110%, no changes in erectile or ejaculatory function and a retreatment rate of 9% at 3 years. [96][97][98] Long term durability studies are pending.…”

Section: Temporary Implantable Nitinol Device (Itind)mentioning

confidence: 99%

UPDATE – 2022 Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH)

Aubé-Peterkin

Evans

Elmansy

et al. 2022

CUAJ

View full text Add to dashboard Cite

These guidelines are directed toward the typical male patient over 50 years of age, presenting with LUTS and benign prostatic enlargement (BPE) and/or benign prostatic obstruction (BPO). It is recognized that men with LUTS associated with causes other than BPO may require more extensive diagnostic workup and different treatment considerations. We acknowledge that not all patients identify as male. These guidelines should also be applicable to non-binary people, transwomen, and any patients who may have anatomical features of a cis-male genitourinary tract such as a prostate. It is our intent to make these guidelines inclusive to all persons experiencing lower urinary tract symptoms or an enlarged prostate.In this document, we will address both diagnostic and treatment issues. Diagnostic guidelines are described in the following terms as: mandatory, recommended, optional, or not recommended. The recommendations for diagnostic guidelines and principles of treatment were developed on the basis of clinical principle (widely agreed upon by Canadian urologists) and/or expert opinion (consensus of committee and reviewers). The grade of recommendation will not be offered for diagnostic recommendations. Guidelines for treatment are described using the GRADE approach 4 for summarizing the evidence and making recommendations Diagnostic guidelinesThe committee recommended minor revisions in regard to diagnostic considerations as outlined in the 2018 CUA BPH guideline. 1 MandatoryIn the initial evaluation of a man presenting with LUTS, the evaluation of symptom severity and bother is essential. Medical history should include relevant prior and current illnesses, as well as prior surgery and trauma. Current medication, including over-the-counter drugs and phytotherapeutic agents, must be reviewed. A focused physical examination, including a digital rectal exam (DRE), is also mandatory. Urinalysis is required to rule out diagnoses other than BPH that may cause LUTS and may require additional diagnostic tests. [1][2][3]5,6,7 -History -Physical examination including DRE -Urinalysis Recommended Symptom inventory (should include bother assessment)A formal symptom inventory (e.g., International Prostate Symptom Score [IPSS] or AUA Symptom Index [AUA-SI]) is recommended for an objective assessment of symptoms at CUAJ -CUA Guideline Elterman et al CUA guideline: BPH/LUTS 3

show abstract

Section: Temporary Implantable Nitinol Device (Itind)mentioning

confidence: 99%

UPDATE – 2022 Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH)

Aubé-Peterkin

Evans

Elmansy

et al. 2022

CUAJ

View full text Add to dashboard Cite

show abstract

“…The glands greater than 80 mL are generally not candidates for minimally invasive transurethral procedures and studies performed on water vapor surgery (Rezum, Boston Scientific, Marlborough, MA) and temporary implantable nitinol device (iTIND, Medi-Tate Ltd, Israel) and also prostatic urethral lift (PUL, Urolift, Neotract Inc., Pleasanton, CA) were all performed in populations with prostates smaller than 80 mL. [35][36][37] Additionally, broad-based median lobes were considered as risk factors of a poor response to Rezum, PUL, and iTIND. Aquablation (Aquabeam; PROCEPT BioRobotics, Redwood City, CA) is a novel technique using real-time ultrasound imaging combined with a highvelocity waterjet to resect prostate tissue.…”

Section: Segmental Morphology and Median Lobe Hypertrophy And Prostat...mentioning

confidence: 99%

Updates on Preprocedural Evaluation and Patient Selection for Prostatic Artery Embolization

Rostambeigi

Golzarian

Little

2022

Semin intervent Radiol

View full text Add to dashboard Cite

Prostatic artery embolization (PAE) is a safe and effective treatment for benign prostatic hyperplasia. Patient evaluation is a critical and important part of this growing practice. History taking should include symptoms score evaluations for lower urinary tract symptoms, erectile function, and prostatitis symptoms score. The objective evaluations commonly include measurement of prostate specific antigen, postvoid residual volume, and uroflowmetry as well as urodynamic studies in selective patients. Imaging evaluation may include computed tomography angiography or magnetic resonance angiography, elucidating prostate volume, prostate gland morphology, vasculature, and prostate cancer. With evolving knowledge on PAE, we aim to discuss patient evaluation and selection based on updated evidence and discuss specific scenarios.

show abstract

“…Data of the 3-year follow-up were available for 50 patients. For these patients, Amparore et al [25 More recently, De Nunzio et al [26] published an interim report of the first 70 patients enrolled in the MT06 study. It is a single-arm, prospective study conducted among urologic centers in Italy and Spain.…”

Section: Itindmentioning

confidence: 99%

Functional Results after First- and Second-Generation Temporary Implantable Nitinol Device (TIND) for BPH: A Narrative Review of the Literature

Cillis

Volpi

Checcucci

et al. 2022

Curr Bladder Dysfunct Rep

Self Cite

View full text Add to dashboard Cite

Purpose of review In the last decades, new promising technologies for the treatment of BPH-related lower urinary tract symptoms (LUTS) have been widely experienced in clinical practice, with the aim of offering fewer complications but similar functional outcomes compared with the gold standard transurethral resection of the prostate (TURP). Among these so-called minimally invasive approaches, transurethral implantation of first- and second-generation temporary implantable nitinol device (TIND and iTIND, respectively) (Medi-Tate; Medi-Tate Ltd., Or Akiva, Israel) has been included by the European Association of Urology (EAU) Guidelines as one of the available alternative treatments to TURP. In the present paper, we conducted a systematic review of the current literature on TIND and iTIND implantation focusing on functional outcomes. Medline, Embase, and Cochrane databases were queried for relevant Literature in May 2021. Recent findings Data regarding the use of temporary implantable nitinol device for BPH are still very limited, with only seven studies currently available in Literature. All the studies report that both TIND and iTIND procedures are safe, effective, and well tolerated. Moreover, such treatments seem to not affect patient’s sexual and ejaculatory functions. Summary Current clinical evidence suggests that temporary implantation of first- and second-generation temporary implantable nitinol devices are valid options for the minimally invasive surgical treatment of BPH-related LUTS. Further studies are required in order to confirm the functional results, especially over a long-term follow up.

show abstract

3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction

Cited by 43 publications

References 25 publications

UPDATE – 2022 Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH)

UPDATE – 2022 Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH)

Updates on Preprocedural Evaluation and Patient Selection for Prostatic Artery Embolization

Functional Results after First- and Second-Generation Temporary Implantable Nitinol Device (TIND) for BPH: A Narrative Review of the Literature

Contact Info

Product

Resources

About